Scientific, Economic, Social and Ethical Implications of Developing Ethnic-Specific Therapeutics, Such As BiDil The National Human Genome Center and Department.

Slides:



Advertisements
Similar presentations
CR-1 ATACAND ® (candesartan cilexetil) Cardiovascular and Renal Drugs Advisory Committee Bethesda, Maryland July 18, 2002 C.
Advertisements

Genetics and “Race” “Understanding The Genetic Basis of Common Disease and Human Traits” May 1, 2007 Vence L. Bonham, Jr., J.D. Senior Advisor to the Director.
JNC 8 Guidelines….
EXTENDING THE “FUNDAMENTAL CAUSE” THEORY TO EXPERIENCES OF RACISM AMONG AMERICAN AND CARIBBEAN PEOPLE OF AFRICAN DESCENT Arthur L Whaley, PhD, DrPH Jackson.
 Schwartz, R. S “Racial Profiling in Medical Research.” New England Journal of Medicine 344(18): 1392 –  Winker, M. A “Measuring.
Is Genomics the Cure for Disparities? Francis S. Collins, M.D., Ph.D. National Leadership Summit to Eliminate Racial and Ethnic Disparities in Health January.
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
NHANES III Prevalence of Hypertension* According to BMI
Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.
The Pursuit of Better Medicines through Genetic Research Terri Arledge, DVM US Department Head Drug Development Genetics.
Www2.warwick.ac.uk/go/cappuccio Body size and blood pressure: a collaborative analysis of 18,072 participants from Africa and the African diaspora FP Cappuccio,
1 Pharmacogenomics and American Indian Populations: Drug Development in the Context of Health Disparities Morris W. Foster, Ph.D. Department of Anthropology.
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Hypertension.
DIABETES AMONG AMERICAN INDIANS: A CASE STUDY IN MOVING FROM HEALTH DISPARITIES TO HEALTH EQUITY Ronny A. Bell, PhD, MS Professor, Department of Epidemiology.
Dallas Dooley Dana Hogan.   Topeka’s Population in 2009= 124,331  Increase of 1.6% from 2000  Female= 64,634  Male= 59,697  Median Age= 36.5 years.
Should the Government Support the Development of Race-based Medicines? Jean Wolph, Kentucky Writing Project RSPDI A Mini-Unit on Teaching Argument: Claims.
Ethical Problems in Pharmacogenomic Research
Randomized, double-blind, multicenter, controlled trial.
TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.
Assessing A-HeFT and PEACE Eric J Topol MD Provost and Chief Academic Officer Chair, Department of Cardiovascular Medicine Cleveland Clinic Foundation.
1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.
Otis W. Brawley M.D. Director, Georgia Cancer Center Associate Director, Winship Cancer Institute Professor of Hematology, Oncology, and Epidemiology Emory.
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
Framingham meets genomics William P Castelli MD Director Framingham Cardiovascular Institute Adjunct-Associate Professor of Medicine Boston University.
DION GALLANT, MD PRIMARY CARE SERVICE LINE MEDICAL DIRECTOR PRESBYTERIAN MEDICAL GROUP JNC 8.
The Human Genome Project: prospects for cardiology Claude L’Enfant MD Director, National Heart, Lung, and Blood Institute National Institutes of Health,
Analyzing NCHS Drug Data Amy B. Bernstein, Sc.D. Presented at the NCHS Board of Scientific Counselors Meeting January 28, 2005 U.S. DEPARTMENT OF HEALTH.
1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Should developing countries continue to use older drugs for essential hypertension? A prescription survey in South Africa suggested that prescribers were.
Infectious Disease Caused by invading organisms such as bacteria, viruses, or fungi. Throughout evolution, disease has exerted selective pressures on human.
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
CRDAC Questions June 15, 2005 Antihypertensive drugs, with few exceptions, have no outcome claim in their labeling. This is inconsistent with their approval.
University of South Florida College of Nursing Tampa, Florida.
Elizabeth Ofili, M.D., M.P.H., F.A.C.C. Professor of Medicine and Chief of Cardiology Director, Clinical Research Center Associate Dean of Clinical Research.
Impact of ISDN-hydralazine on mortality and morbidity of African-American patients with Heart Failure A-Heft Trial Presented at American Heart Association.
Social Factors Matter Class, Race and Gender in Health Outcomes.
BARBER-1 (Barber-Assisted Reduction in Blood Pressure in Ethnic Residents) A randomized study investigating the effect of having the local barber encourage.
Polypill x Aspirin Project Groups 3 and 4
Is there evidence to justify different claims for different drug classes? Presentation to: Cardiovascular & Renal Drugs Advisory Committee Food & Drug.
BiDil: Patenting “blackness” Critique of the So-Called “Race” – Specific Heart Failure Drug Presentation to the FDA, 16 June 2005 Dedicated to the memory.
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:
Saleem Jessani 1, Rasool Bux 1 and Tazeen H. Jafar 1,2. 1 Aga Khan University, Karachi, Pakistan 2 Duke-NUS Graduate Medical School, Singapore Socio-demographic.
Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/AHA 2011 Expert Consensus Document on Hypertension.
Health Equity and Increasing Medication Adherence for High Blood Pressure Control Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH Professor of Medicine.
Management of Hypertension according to JNC 7
Analysis of Human Variation
Hypertension guidelines What’s all the controversy about 2015
Health Disparities Affecting Minority Populations
Exercise Adherence in Patients with Diabetes: Evaluating the role of psychosocial factors in managing diabetes Natalie N. Young,1, 2 Jennifer P. Friedberg,1,
Women Are More Likely to Address High Blood Pressure
All-cause mortality by treatment group
Pharmacogenetics: Implications of race and ethnicity on defining genetic profiles for personalized medicine  Victor E. Ortega, MD, Deborah A. Meyers,
United States Preventive Services Task Force: Recommendations for ABPM
David J. Hyman, MD, MPH Professor of Medicine and
Progress and Promise in RAAS Blockade
Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE.
The Hypertension in the Very Elderly Trial (HYVET)
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Originally presented by Drs. Daniel Levy, Richard H. Grimm, Steven E
“The Roles of Race and Representation in Learning Health Systems:
G. Michael Felker et al. JCHF 2014;2:
Pamela E. Scott et al. JACC 2018;71:
Presentation transcript:

Scientific, Economic, Social and Ethical Implications of Developing Ethnic-Specific Therapeutics, Such As BiDil The National Human Genome Center and Department of Cardiology College of Medicine, Howard University Charles N. Rotimi, PhD Professor and Director Genetic Epidemiology National Human Genome Center College of Medicine, Howard University June 16, 2005

The Genome in Black and White (and Gray) October 10, 2004 (New York Times) By ROBIN MARANTZ HENIG In the not-too-distant future, if you're black and have heart failure, drug- company researchers predict you'll be able to go to the doctor and walk out with a prescription tailor-made for you. Well, not tailor-made, exactly, but something that seems to work in people a lot like you. Well, not a lot like you, exactly, except that they're black, too. In this not-too-distant future, if you're black, your doctor will be able to prescribe BiDil, the first drug in America that's being niche-marketed to people of a particular race -- our first ethnic medicine. African American Heart Failure Trial (A-HeFT)

The question is – “Who is Black?” Australian Aboriginals Masi, Kenya Surma bribe from Ethiopia Confusion: Group identity is confused with group ancestry. For example, the group identity “African Americans” does not reflect a single path of ancestry. Some African Americans may have as much as 40% or 70% Caucasian alleles, while others may have 5% or 10%

All Black Populations Are Equal Problem: leads to group characterization without adequate justification. “The more frequent occurrence of hypertension in black (Afro-Caribbean) subsamples throughout the Caribbean has been traced to ancestral populations in West Africa and is thus at least partially attributable to gene flow from an originally high- prevalence area…” Halberstein RA. Human Biology In the review by Kaufman JS and Hall SA. Epidemiology January 2003 Prevalence of Hypertension by Mean Body Mass Index Among Populations of the African Diaspora North America Caribbean West Africa Cooper RS, Rotimi CN, et al. AJPH. 1997

N=85,000

Study Design Issues and Data Interpretation Blood pressure response to ACE inhibitors 4.6 mm Hg SD=14 mm Hg SD=12 mm Hg African- American European- American Similar drug-associated changes in diastolic BP was 90% (95% CI: 92 to 98) for Calcium blockers. 81% (95% CI: 76 to 86) for ACE (Sehgal, Hypertension 2004) Conclusion: the majority of whites and blacks have similar responses to commonly used antihypertensive drugs. Clinical decisions to use a specific drug should be based on other considerations such as efficacy in individual patients, compelling indications, and cost.

We Advocate For 1. Labeling with language indicating the fact that BiDil does not replace existing drugs for the treatment of heart failure and that although it was tested only among African Americans, it may indeed be an effective treatment for heart failure patients who may not self identify (or be identified) as African Americans. 2.BiDil should not be approved as an African American ONLY drug (and by extension – all “black” people). The history of drug development and approval does not support ethnic labeling. Due to political, social and economic forces, biomedical research was almost exclusively conducted in people, especially men, of European descent. Results of such studies were extrapolated to other groups without such labels as “White Drug”. In the end, the BiDil story will have similar outcome; if the drug continues to be effective in the treatment of heart failure, the global subset of individuals with heart failure who will benefit from the drug will not be accurately described by the label 'African American'.

We Advocate For 3.Strategies that promote overall health not simply the absence of disease (e.g, heart failure). What good is a drug that reduces mortality from heart failure by 43% if: a.Because of patent, an otherwise cheap generically available therapeutics becomes unaffordable; b.It exacerbates racism with resulting increased hypertension and associated complications, including heart failure) due to increased psychosocial stressors; c.It leads biomedical research down a wrong path by suggesting, without proper scientific justification, that the so-called racial categories are biological?